Abstract. The locus of inhibition of nicotinamide adenine dinucleotide, reduced form (NADH) oxidation in mitochondria by rotenone, piericidin A, and barbiturates is considered in the light of available information. Most lines of evidence indicate that the point of inhibition is on the 02 side of NADH dehydrogenase. Kinetic experiments on the substrate-induced appearance of the electron paramagnetic resonance signal at g = 1.94 in membrane preparations (ETP) reveal that these inhibitors do not interfere with the reduction of the electron paramagnetic resonance detectable iron by NADH. Our spectrophotometric studies on complex I give no evidence for absorbance differences between untreated and rotenone or piericidin inhibited preparations, which can be attributed to nonheme iron. Whatever changes were observed appear to be due to cytochromes. These experiments, therefore, do not support the idea that in inhibited preparations electron transport is interrupted between the flavin and nonheme iron components of NADH dehydrogenase.
rotenone, piericidin, and amytal.10 The inhibition characteristics are quite different, however, in form II from those observed in mitochondria. 10' 11 Form II has been regarded by some workers as a relatively unmodified enzyme, preexisting as such in mitochondria, with differences in properties between bound and soluble form ascribed to the influence of the environment in the particle-bound state.12-'4 Hatefil5 visualizes the particulate enzyme as a complex of enzymes, consisting of a flavoprotein, a nonheme iron protein, and structural protein, which may be dissociated with urea. 6 The postulated flavoprotein component corresponds to form II. The experimental basis offered for the existence of a separate flavoprotein and a nonheme iron protein is not unambiguous. 16 Singer et al. 16 ' 17 favor a third interpretation, that NADH dehydrogenase is a single enzyme composed of many polypeptide chains held in a strained conformation, stabilized by the membrane structure so that a variety of treatments fragment it into numerous polypeptide units of which form II is but one of the many products. In view of its properties, form I is regarded as closer to the native form of the enzyme, while form II is grossly altered during fragmentation. 16, 18 Contrary to earlier views,19-2' the majority of investigators now agree that amytal, rotenone, and piericidin inhibit NADH oxidation on the 02 side, rather than the substrate side, of the flavoprotein,8' 15, 22-27 but there is no accord on whether the block occurs before or after the nonheme iron components of the enzyme. The fact that normal reactivity with ferricyanide is not inhibited by these reagents in ETP or in form I favors an inhibition site after the electron paramagnetic resonance (epr) detectable nonheme iron, since NADH-ferricyanide activity and the epr signal at g = 1.94 seem closely interdependent.28 Further, in ETP preparations inhibited by rotenone, piericidin, or amytal the epr-detectable iron is reduced to nearly the same extent by NADH as in untreated ones,25 although, as expected, there is inhibition of the reduction of the nonheme iron atoms associated with succinate dehydrogenase and cytochromes b and cl. Normal reduction of nonheme iron of NADH dehydrogenase in rotenone-inhibited particles had been previously reported. 26 Further information was needed on the possible influence of these inhibitors on the rate of reduction of the epr-active iron atoms of NADH dehydrogenase because the earlier experiments were performed by manual mixing and the turnover number of the enzyme is very high.17 The epr spectra of untreated and piericidin-inhibited ETP are shown in Figure 1 , as recorded at different times.
The copper signal of cytochrome oxidase in the inhibited sample has a clearly nonheme iron of succinate dehydrogenase is reduced in the presence of blastmycin while it remains oxidized in the presence of piericidin (Table 1) . These experiments support the view that rotenone, piericidin, and amytal act on the 02 side of the epr-detectable iron components of the NADH dehydrogenase of heart. Recent studies with Candida utilis also support this notion. 27 A different interpretation was reached in studies involving measurements of absorbance changes at 460 -510 mi induced by NADH in particles (a complex I + III preparation and complex I, containing some cytochromes b and cl, and supplemented with cytochrome c and its oxidase); rotenone and piericidin decreased by about 50 per cent the bleaching at this wavelength pair.'5 These absorbance changes were ascribed to reduction of the nonheme iron of NADH dehydrogenase, which led to the conclusion that these inhibitors act between the flavin and iron components. '5 If the color changes described by Hatefi were indeed due to some or even most of the nonheme iron of the dehydrogenase, this would not necessarily conflict with our epr results, since only a fraction of the 16 to 18 atoms of nonheme iron of the dehydrogenase are epr detectable,28 but all might contribute to absorbance changes. However, it has been emphasized" ' 17, 22 same in inhibited particles as in the control. The actual figures for the absorbance change at this wavelength pair were: control, 0.034; rotenone inhibited, 0.033; piericidin inhibited, 0.034. The small differences in the absolute spectra of control and inhibited samples were almost certainly due to contaminating cytochromes30 in the preparation (see dithionite curve), the reduction of which is blocked by these inhibitors. The present data support and extend other recent spectrophotometric studies on ETP. 25 The involvement of nonheme iron in the binding of piericidin and rotenone and in their inhibition of NADH oxidation has also been implicated from other lines of evidence. C. utilis, grown in an iron-deficient medium, is not sensitive to piericidin and rotenone and lacks nonheme iron, without a major impairment of respiration, incubation of the Fe-deficient cells with FeSO4 reverses these effects.3' A recent reports on C. utilis concludes, however, that the nonheme iron content and the g = 1.94 signal are not related to the piericidin-sensitive site.
Another recent report24 presented optical and epr spectra indicating that at low levels of rotenone, which allow a slow reoxidation of NADH by ETP, a component with the properties of a nonheme iron compound remains partially reduced; this was interpreted to mean that rotenone reacts with the reduced form of the nonheme iron component characterized by the well-known signal at ql = 1.94, g11 = 2.0 in reduced ETP and that this may be the mechanism of rotenone inhibition of NADH oxidation. The epr data in Figure 1 and Table 1 and our earlier results25 do not contradict these observations directly, since the experiments were designed to test whether the epr-detectable nonheme iron of NADH dehydrogenase is reduced at the same rate in untreated and piericidin inhibited samples, as would be expected if the block were on the 02 side of this component. There is no evidence, however, in the epr signal of the nonheme iron component of NADH dehydrogenase that the iron is in a different environment when rotenone or piericidin is added, as compared with untreated ETP, and epr signals are in general extremely sensitive to even minor changes in the environment of the paramagnetic species. It is also known that rotenone is strongly bound to oxidized ETP (without NADH), indicating that nonheme iron does not have to be in the reduced state for efficient binding.
Final areas for consideration are the quantitative aspects32 of rotenone and piericidin binding and the possible role of the NADH dehydrogenase protein in this binding. These inhibitors, as well as barbiturates, compete for and inhibit at the same site(s)." Use was made of labeled inhibitors and of bovine serum albumin (BSA) to differentiate two types of sites. Specific binding site(s) is defined in this context as a site(s) from which labeled rotenone or piericidin A is not removed by BSA and which is responsible for inhibition in the NADH dehydrogenase-ubiquinone region. There are also a number of unspecific binding sites for rotenone and piericidin A in mitochondria and submitochondrial particles from which BSA readily dissociates these inhibitors. 3 The specific binding site titer for rotenone and piericidin is 1.5 to 2 moles per mole of NADH dehydrogenase in ETP and approximates 1 in simpler particles, such as complex I or complexes I + III.33 A more precise value,34 determined from Scatchard35 plots, is 2 for ETP (Fig. 3) from specific activity in the phospholipase A, as well as with protei-modifyig ferricyanide assay, all as in agents, causes extensive translocation of the labeled previous work.33 A, ETP inhibitor from specific sites to unspecific ones, from ments with 1 and 2 mg/ml which they are removed by BSA.33 It is appropriprotein during titration, re-ate, therefore, to reopen this question. Three types spectively; concentration of of comparisons are involved: (a) the rates of release, the inhibitor varied from under the influence of phospholipase A, of "C-13 m;&M to 1.3 sM. Samples were incubated for 1 hr at piericidin A and of NADH dehydrogenase from 00 before BSA wash. B, ETP labeled at the specific site (Fig. 4) modifies the dehydrogenase on subsequent piericidin binding (Fig. 3) . Special experimental conditions are necessary in comparing the rates of release by phospholipase A of radioactivity and of NADH dehydrogenase activity from ETP labeled at the specific site(s) with 14C-piericidin A (Fig. 4) ; this is so because piericidin A is not released into solution under these conditions but is moved to unspecific sites. Accordingly, the preparation was extracted with BSA periodically in the course of digestion to follow this translocation. As in the solubilization of the enzyme, two digestion steps were used: a five-minute treatment with low concentration of phospholipase, which removes inert protein but no dehydrogenase, and a longer digestion with additional phospholipase. In the first step, some 14C-piericidin is released without solubilization of any enzyme while in the second step the dehydrogenase is released faster than piericidin (Fig. 4) .
In the converse experiment (Fig. 5) salyl addition to particles which are first in-digested with venom as in Fig. 4 , cubated ("pre-conditioned") with NADH: with centrifugations in between in these conditions both oxidase and ferricya-digestions; in the second digestion aliquots were removed and centrinide activity are inhibited.36' 3 Treatment fuged; the supernatants were asof ETP with 30 AM mersalyl, with or without sayed for extracted NADH dehy-"pre-conditioning," markedly changes the drogenase activity and the residues binding curvefo l4CnA16, 34 andthe were labeled at the specific sites (2 binding curve for 'C-piericidin A' and the BSA washes) as in Fig. 3 . specific site titer is reduced from 2.0 to about 1.2 (Fig. 3) . But once piericidin is bound at the specific sites, mersalyl treatment does not release it, although modification of the dehydrogenase by the mercurial is still evident.'6 These experiments are compatible with, but do not prove conclusively, the hypothesis that the native conformation of NADH dehydrogenase is essential for normal piericidin binding and that the flavoprotein may be one of the anchoring sites of rotenone, piericidin, and barbiturates. * Supported by grants from the U.S. Public Health Service (HE 10027, GM 12394, and GM 00049), the National Science Foundation (GB 8248), the American Heart Association (67 706), the American Cancer Society (P531), and the A.E.C. (contract AT(11-1)-34. 
